Skip to main content
. 2019 Nov 13;45(1):162–174. doi: 10.3892/ijmm.2019.4404

Figure 7.

Figure 7

Effects of the MEK inhibitor PD0325901 on the expression and phosphorylation of MAPK signaling pathway-related molecules in MDA-MB-231 breast cancer cells. (A) Effect of PD0325901 on the mRNA expression levels of MAPK signaling pathway-related genes in breast cancer cells by RT-qPCR. (B) Effect of PD0325901 on the protein expression levels of MAPK signaling pathway-related molecules in breast cancer cells by western blot analysis, and (C) statistical analysis of the western blot bands. APP overexpression in breast cancer cells treated with PD0325901. (D) mRNA expression level of MAPK signaling pathway-related genes in breast cancer cells was detected by RT-qPCR. (E) Protein expression levels of MAPK signaling pathway-related molecules in breast cancer cells were determined by western blot analysis. (F) Statistical analysis of the relevant western blot bands. All the experiments were performed in triplicate. Data are presented as the mean ± SD. *P<0.05. MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; APP, amyloid precursor protein; RT-qPCR, reverse transcription-quantitative PCR; MEK4, mitogen-activated protein kinase kinase 4; OE, overexpression; p-, phosphorylated; t-, total; NS, not significant.